Published Date : Jul 10, 2017
After bagging scores of applauds at the G20 Hamburg Summit on the lines of finance, business, and technology, India has attracted investments from global giants in the pharmaceutical domain. Recently, GlaxoSmithKline (GSK) Pharmaceuticals, a worldwide healthcare and pharma company, has announced its investment of a INR 1,000.0 cr in a new state-of-the-art plant in Karnataka. Set to commence production next year, the unit will produce over a billion capsules and eight billion tablets annually. On an initial basis, the unit will supply an array of solid dose form products. The company has recognized the scope of broadening its global vaccines and respiratory drugs pipeline in a worthwhile India market.
Another INR 115 Crore Investment for New Dedicated Eltroxin Facility
GSK will be looking to accommodate the requirement of providing its high-quality medicines to patients through a reliable, secure supply via the upcoming Karnataka facility in addition to the Nashik manufacturing facility. The company will execute an assessment of new offerings from its international vaccines and respiratory pipeline and review them for a conceivable launch in the country. In the backdrop of a 30.0% of its international pharmaceutical volumes sold in India, GSK will also be reviewing complementary inorganic prospects.
GSK has also made its intentions clear to upgrade its Nashik facility. It has invested a INR 115.0 cr to build a dedicated facility for manufacturing eltroxin. The new eltroxin facility will commence operations in 2018. Six of GSK makes have already made to the list of top 50 Indian pharma market (IPM) brands. With a view to maintain competitive margins, the company will be looking to reengineer its business models.